Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC

Shilpa Medicare (SML) surged 16.25% to Rs 657.30 after the company's CDMO customer, Unicycive Therapeutics, Inc. has reported positive results from pivotal clinical trial of Oxylanthanum Carbonate (OLC) to treat kidney diseases.